2022年11月14日

*所需領域- fb -102繼續向臨床發展，並在多種指征中擁有巨大的市場潛力-任命Scott Brun醫學博士為董事會成員，加強了領導力- -截止2022年第三季度，Forte Biosciences, Inc. (www.fortebiorx.com)(納斯達克:FBRX)是一家專注於自身免疫疾病的生物製藥公司，今天宣布了2022年第三季度的業績，並提供了業務更新。“Forte的主要項目FB-102取得了出色的進展，這是團隊辛勤工作和勤奮努力的直接結果。FB-102在各種適應症中具有巨大的潛力，市場潛力超過60億美元。Forte Biosciences董事長兼首席執行官Paul Wagner博士說。“FB-102預計將於2023年底或2024年初投入臨床。除了FB-102，複地團隊還將繼續探索管道開發的其他機會，以推動長期價值創造。”2022年11月，複地任命Scott Brun醫學博士為董事會成員，進一步加強了複地董事會的實力。Brun博士目前是Abingworth的風險合夥人，除了他的谘詢業務，他也是Horizon Therapeutics的高級顧問，以及Launch Therapeutics的高級醫療顧問。Brun博士此前曾在艾伯維擔任多個行政職務，最近擔任艾伯維風險投資公司(AbbVie Ventures)的主管，此前擔任藥物開發主管。布倫博士在約翰霍普金斯大學醫學院獲得醫學博士學位。 “Given Dr. Brun’s extensive experience in pharmaceutical product development, R&D and scientific affairs, his agreeing to join our board is pivotal for Forte. We are extremely fortunate to have board members of Dr. Brun’s caliber join the team to help guide the pipeline development.” said Paul Wagner, Ph.D., Forte’s Chairman and CEO. Forte ended the third quarter of 2022 with approximately $44.0 million in cash and cash equivalents. Forte had approximately 21.0 million shares of common stock outstanding as of September 30, 2022. Third Quarter 2022 Operating Results Research and development expenses were $1.4 million and $5.7 million for the three months ended September 30, 2022 and 2021, and $3.1 million and $12.5 million for the nine months ended September 30, 2022 and 2021, respectively. The decreases in 2022 were primarily due to the wind down of our FB-401 program as the Company began the shift in development activities to autoimmune indications with FB-102. While research and development expenses decreased in 2022 compared to 2021, we anticipate research and development expenses to increase in the future as we continue to develop our current lead product candidate, FB-102. General and administrative expenses were $2.0 million for the three months ended September 30, 2022 and 2021. General and administrative expenses remained relatively flat as an increase in legal and professional expenses of $0.4 million was mostly offset by a decrease of approximately $0.4 million in payroll and related expenses. General and administrative expenses were $5.9 million and $5.7 million for the nine months ended September 30, 2022 and 2021, respectively. The increase of $0.2 million was primarily due to an increase in stock-based compensation expenses. Net losses per share were ($0.18) and ($0.54) for the three months ended September 30, 2022 and 2021, and ($0.56) and ($1.34) for the nine months ended September 30, 2022 and 2021, respectively. FORTE BIOSCIENCES, INC.